Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults

Inclusion Criteria: * patient presenting with Chronic Non Allergic and Non Infectious Rhinitis capable of benefiting from corticosteroid therapy administered via the nasal route. * patient with chronic rhinitis of minimum duration 12 weeks, whether or not consecutive, per year. * patient with Non Allergic Rhinitis confirmed by negative phadiatop test. * patient presenting a mean global score for the 5 symptoms \>= 5 (nasal obstruction, rhinorrhea, disturbance of sense of smell, sneezing, facial heaviness), or mean score for the 3 main symptoms (nasal obstruction, rhinorrhea, disturbance of sense of smell) \>= 5 (mean for 7 days prior to visit V0). * patient presenting an inflammation score at anterior rhinoscopy or nasal endoscopy \>= 4. Exclusion Criteria: * patient presenting a nasal polyp * patient presenting a severe septal deviation which would interfere with insertion of the nasal spray * patient presenting a nasal cavity tumor * patient presenting a sinus infection * patient presenting a history of endonasal surgery * patient presenting a chronic rhinitis of extrinsic origin (drug-related or food-related rhinitis) or intrinsic origin (hormonal rhinitis, positional rhinitis,atrophic rhinitis, ...) * patient on a program of intensive sports training * patient presenting with : cystic fibrosis, pulmonary mycosis, necrotising vascularitis, immotile cilia syndrome, .... * patient presenting with known immunosuppression, lymphoma * patient presenting with a known cardiovascular, neurological or other medically significant illness * patient presenting with known renal failure, with known glaucoma, with known drug addiction * current antibiotic therapy * corticosteroids administered in the two months prior to admission * patient presenting problems of haemostasis (epistaxis), ophthalmic and/or oro-bucco-nasal herpetic infection. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.